Carlsmed Q2 net loss widens 55.3% to $10.51 million; revenue rises 57% to $18.9 million
CARL•Quarterly results
- Carlsmed posted Q2 revenue of USD 18.9 million, up 57% year over year, driven by rising aprevo procedures across lumbar and cervical.
- Net loss widened to USD 10.5 million; gross margin expanded 3.4 percentage points to 76.8%.
- Operating expenses climbed to USD 25.6 million, led by USD 11.9 million in sales and marketing spending.
- Trained surgeon users rose more than 60% year over year; aprevo cervical reached about 10% of quarterly revenue in its second full quarter.
Guidance and reimbursement update
- Full-year revenue guidance increased to USD 74 million-USD 78 million; CEO Mike Cordonnier cited a CMS reimbursement ruling effective Oct. 1, 2026.
